Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137248 | 0.92 | MET (0.53) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1136979 | 0.86 | HSPB1 (0.44) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL12385724 | 0.85 | HSPB1 (0.47) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1137010 | 0.85 | HSPB1 (0.41) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1137363 | 0.83 | POLB (0.42) | HSPB1METALDH1A1MAPTMAPK1 | |
| SCHEMBL2257136 | 0.83 | MMP13 (0.41) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2257142 | 0.83 | MMP13 (0.41) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL30495862 | 0.82 | CCNT1 (0.44) | HSPB1MET | |
| SCHEMBL1137142 | 0.82 | SLC22A12 (0.41) | HSPB1METCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1891353 | 0.81 | BTK (0.46) | HSPB1CYP19A1CYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | HSPB1 3174/4885MET 545/4885CYP19A1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.